Grantham, Mayo, Van Otterloo & Co (GMO)
REGN icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Regeneron Pharmaceuticals REGN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3M Buy
74,200
+18,847
+34% +$12.8M 0.1% 78
2026
Q1 		$42.8M Sell
55,353
-1,351
-2% -$1.03M 0.11% 83
2025
Q4 		$43.8M Sell
56,704
-4,770
-8% -$3.24M 0.11% 78
2025
Q3 		$34.6M Sell
61,474
-3,809
-6% -$2.15M 0.1% 113
2025
Q2 		$34.3M Sell
65,283
-18,047
-22% -$10.1M 0.1% 106
2025
Q1 		$52.9M Buy
83,330
+20,351
+32% +$14M 0.17% 63
2024
Q4 		$44.9M Buy
62,979
+10,982
+21% +$9.22M 0.15% 82
2024
Q3 		$54.7M Sell
51,997
-5,267
-9% -$5.86M 0.17% 71
2024
Q2 		$60.2M Sell
57,264
-596
-1% -$578K 0.2% 61
2024
Q1 		$55.7M Sell
57,860
-9,240
-14% -$8.79M 0.2% 69
2023
Q4 		$58.9M Buy
67,100
+9,160
+16% +$7.54M 0.26% 63
2023
Q3 		$47.7M Buy
57,940
+5,036
+10% +$3.96M 0.23% 77
2023
Q2 		$38M Sell
52,904
-14,238
-21% -$11M 0.18% 105
2023
Q1 		$55.2M Sell
67,142
-4,000
-6% -$3.02M 0.28% 66
2022
Q4 		$51.3M Buy
71,142
+17,142
+32% +$12.6M 0.27% 68
2022
Q3 		$37.2M Sell
54,000
-2,400
-4% -$1.51M 0.21% 85
2022
Q2 		$33.3M Buy
56,400
+8,500
+18% +$5.53M 0.18% 105
2022
Q1 		$33.5M Buy
47,900
+500
+1% +$316K 0.16% 106
2021
Q4 		$29.9M Sell
47,400
-1,900
-4% -$1.17M 0.14% 121
2021
Q3 		$29.8M Buy
49,300
+800
+2% +$497K 0.15% 116
2021
Q2 		$27.1M Buy
48,500
+6,900
+17% +$3.5M 0.14% 132
2021
Q1 		$19.7M Buy
41,600
+13,444
+48% +$6.55M 0.11% 151
2020
Q4 		$13.6M Buy
28,156
+27,700
+6,075% +$15M 0.08% 168
2020
Q3 		$255K Hold
456
– – ﹤0.01% 715
2020
Q2 		$284K Buy
+456
New +$259K ﹤0.01% 678
2019
Q3 		– Sell
-11,100
Closed -$3.47M – 779
2019
Q2 		$3.47M Buy
11,100
+10,600
+2,120% +$3.53M 0.02% 359
2019
Q1 		$205K Buy
+500
New +$206K ﹤0.01% 679
2013
Q3 		– Sell
-30,600
Closed -$6.88M – 691
2013
Q2 		$6.88M Buy
+30,600
New +$7.13M 0.02% 251

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s REGN Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its Regeneron Pharmaceuticals (REGN) stake by 34% in Q2 2026, buying an estimated $12.8M and bringing the position to 74,200 shares worth $46.3M. The position accounts for 0.1% of the portfolio, ranked #78.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in REGN in Q2 2013 and has held it in 28 quarters since. The position peaked at $60.2M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 74,200 shares of Regeneron Pharmaceuticals worth $46.3M as of Q2 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) bought 18,847 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.8M.
  • Regeneron Pharmaceuticals made up 0.1% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #78 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Regeneron Pharmaceuticals position peaked at $60.2M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.